Mongodb Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Mongodb Inc trades at $323.57 (market cap $26.01B), while Regeneron Pharmaceuticals Inc trades at $676.15 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.7× Mongodb Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals.
| MDB | REGN | |
|---|---|---|
Market Cap | $26.01B | $70.47B |
Sector | Technology | Health |
52-Week High | $440.25 | $812.27 |
52-Week Low | $201.08 | $545.46 |
Enterprise Value | $23.61B | $64.42B |
Dividend Yield | — | 0.56% |
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $324.44, up 3.88% today, with strong analyst support (82% buy ratings) and a $400.39 consensus price target. The stock shows bearish technical signals but has consistently beaten earnings expectations, with Q1 2026 EPS of $1.32 surpassing the $1.19 estimate. Revenue growth remains robust at $2.01B for 2025, though profitability challenges persist with a negative net margin of -1.12%.
MDB presents a growth investment opportunity with accelerating revenue and improving margins, but faces execution risks and competitive pressures. The stock's premium valuation (P/S 9.77) requires sustained high growth, while negative cash flow and ongoing profitability concerns warrant caution despite Wall Street optimism.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Trailing returns across standard periods
Latest headlines on both assets
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →